Novartis Buys Ziarco and Its Potential Eczema Drug

NovartisIn the past one week, there has been a hike of 6 percent in the stocks of Novartis Ag (NYSE: NVS). The new stock price of this Swiss multinational pharmaceutical company is now $71.77.

There was an uptrend in the stock prices after the newly elected President Donald Trump asked for controlling the selling price of the drugs in the market in early December. But if you read below, you will be able you find out the real reason for the stocks of this pharmaceutical company to remain bullish.

In the last week, Novartis acquired Ziarco which is the United Kingdom-based pharmaceutical company. The transaction detail of the company takeover is not revealed to the public yet. However, it is assumed that the total cost of the acquisition is estimated to be a value of $1 billion and it includes royalties and milestones. The figure is revealed by an unnamed Bloomberg media source.

Novartis Mission

ZPL-389 which is a leading investigational drug product of Ziarco is an oral treatment for people suffering from eczema. Eucrisa is a recently approved FDA drug and is propriety of a pharmaceutical company called Anacor. The company has been recently acquired by Pfizer with a huge cost of $4.5 billion. The analysts and investors are of the opinion that ZPL-389 will be a blockbuster drug in the market and attain a lot of popularity among the masses.

According to Novartis, the Committee for Medicinal Products for Human Use (CHMP) has offered its support in Europe for the approval of IIaris drug which is helpful in the treatment of 3 distinct and rare Periodic Fever Syndromes. Based on the results from pivotal Phase III Cluster Study, the recommendation was issued. Once it gets the approval, IIaris will become the primary and sole approved drug for the treatment of Tumor Necrosis Factor-Receptor Associated Periodic Syndrome, Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency and Familial Mediterranean Fever.

The drug Votubia (R) has been recommended by CHMP for EU approval to treat refractory partial-onset seizures in patients with tuberous sclerosis complex (TSC). The company has stated that it got approval from the European Commission for its drug Lucentis (ranibizumab) which is used for the treatment of visual impairment in patients. This is the first drug that has been approved for the treatment of patients who are visually impaired due to choroidal neovascularisation (CNV).

There is short-term support indicated by the historical price chart for the stock at 71.50. There is a rise of MACD indicator in the bullish zone. It suggests that the stock is gaining momentum lately. There is a likely indication of the money flowing in the stock after the positive reading of the Chaikin money flow indicator.

Novartis Stock Price Dec 20th 2016

Novartis Stock Price: December 20th, 2016

So, if you are a trader, you must invest in a high or above contract and generate a lot of profit in return which is valid for one week. You must take the position only when the stock trades is below $72.

Rich Archer

Rich Archer

Hi, my name is Rich Archer. I am living in London. Welcome to Binary Manual. Reach to Binary Options broker reviews and market news here.

No comments

Write a comment
No Comments Yet! You can be first to comment this post!

Write a Comment